AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24308728 — intervention group
Group type: COMPARATOR
Intervention: Brief anti-smoking intervention (for both groups).
Number of subjects: 444
Study 21451393 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundoplication (I)
Number of subjects: 137
Study 21451393 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet posterior partial fundoplication (II)
Number of subjects: 137
Study 19301132 — intervention group
Group type: EXPERIMENTAL
Intervention: NICO monitor with ver. 4.2 software
Number of subjects: 42
Study 19301132 — intervention group
Group type: EXPERIMENTAL
Intervention: NICO monitor with ver. 5.0 software
Number of subjects: 42
Study 19301132 — intervention group
Group type: COMPARATOR
Intervention: Continuous cardiac output (CCO)
Number of subjects: 42
Study 16719652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradeoff size
Number of subjects: 0
Study 16719652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediating effect of sacrifice
Number of subjects: 0
Study 16719652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediating effect of argumentation
Number of subjects: 0
Study 15771223 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 4656
Study 15771223 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4656
Study 11775730 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic, isoperistaltic gastrojejunostomy, jejunojejunostomy, and hepaticojejunostomy after cholecystectomy
Number of subjects: 44
Study 11775730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepaticojejunostomy and antecolic, antiperistaltic gastrojejunostomy after cholecystectomy
Number of subjects: 44
Study 11775730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 44
Study 9257362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol/ipratropium bromide HFA134a inhaler (100 micrograms fenoterol/40 micrograms ipratropium bromide)
Number of subjects: 52
Study 9257362 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CFC inhaler (Berodual) (100 micrograms fenoterol/40 micrograms ipratropium bromide)
Number of subjects: 52
Study 9257362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8275618 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 12
Study 17165348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.02 mg/kg
Number of subjects: 40
Study 17165348 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal saline (ITS)
Number of subjects: 40
Study 29683914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-periodized (NP)
Number of subjects: 33
Study 29683914 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional periodization (TP)
Number of subjects: 33
Study 29683914 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (UP)
Number of subjects: 33
Study 29683914 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study 26652763 — intervention group
Group type: EXPERIMENTAL
Intervention: MCFA-rich diet for 14 days
Number of subjects: 16
Study 26652763 — intervention group
Group type: COMPARATOR
Intervention: LCFA-rich diet for 14 days
Number of subjects: 16
Study 26652763 — intervention group
Group type: EXPERIMENTAL
Intervention: MCFA-rich diet
Number of subjects: 16
Study 26301875 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 20 Hz rTMS applied to the left primary motor cortex (M1) for 5 consecutive days
Number of subjects: 11
Study 26301875 — intervention group
Group type: COMPARATOR
Intervention: Sham 20 Hz rTMS applied to the left primary motor cortex (M1) for 5 consecutive days
Number of subjects: 11
Study 26301875 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG changes
Number of subjects: 11
Study 23378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 206
Study 23378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent oversizing
Number of subjects: 206
Study 23378150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid rich plaque at proximal edge
Number of subjects: 206
Study 23378150 — intervention group
Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 206
Study 21636319 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment guided by EMG
Number of subjects: 26
Study 21636319 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin treatment based on clinical judgement alone
Number of subjects: 26
Study 18438209 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning group (LG)
Number of subjects: 12
Study 18438209 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 12
Study 17062965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 microg x kg(‐1) x min(‐1) of hANP
Number of subjects: 150
Study 17062965 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hANP)
Number of subjects: 150
Study 12746037 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit gateway message ads
Number of subjects: 418
Study 12746037 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit gateway message ads
Number of subjects: 418
Study 12746037 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 418
Study 10984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated screws
Number of subjects: 24
Study 10984710 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stainless steel screws
Number of subjects: 24
Study 7992901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7992901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (0.4 mg.kg-1 bolus followed by 30 micrograms.kg-1.min-1)
Number of subjects: 40
Study 7992901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3-4 micrograms.kg-1 oral)
Number of subjects: 40
Study 7992901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lidocaine (2 ml of 4% spray)
Number of subjects: 40
Study 7992901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 40
Study 2608700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg pessary
Number of subjects: 83
Study 2608700 — intervention group
Group type: COMPARATOR
Intervention: 1700 micrograms film
Number of subjects: 83
Study 4219401 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% amino acid solution with 10% carbohydrates (sorbitol, xylitol)
Number of subjects: 40
Study 4219401 — intervention group
Group type: COMPARATOR
Intervention: Conventional basic electrolyte solution
Number of subjects: 40
Study 31575306 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum noise reduction (NR) setting
Number of subjects: 20
Study 31575306 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum directional setting (broadband directionality)
Number of subjects: 20
Study 30896603 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (4 cycles of 5‐minute right upper limb ischemia and 5‐minute reperfusion)
Number of subjects: 130
Study 30896603 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 130
Study 30896603 — intervention group
Group type: COMPARATOR
Intervention: Sham preconditioning (4 cycles of 5‐minute right upper limb pseudo ischemia and 5‐minute reperfusion)
Number of subjects: 130
Study 30896603 — intervention group
Group type: COMPARATOR
Intervention: Sham preconditioning
Number of subjects: 130
Study 28100130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (8°C)
Number of subjects: 12
Study 28100130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool water immersion (22°C)
Number of subjects: 12
Study 28100130 — intervention group
Group type: COMPARATOR
Intervention: Control (rested in a seated position)
Number of subjects: 12
Study 26074331 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum inspiratory pressure (MIP)
Number of subjects: 40
Study 26074331 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum expiratory pressure (MEP)
Number of subjects: 40
Study 24127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept 2 mg/kg
Number of subjects: 215
Study 24127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept 4 mg/kg
Number of subjects: 215
Study 24127346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept
Number of subjects: 215
Study 22516856 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses (CFO)
Number of subjects: 154
Study 22516856 — intervention group
Group type: COMPARATOR
Intervention: Sham orthoses (Control)
Number of subjects: 154
Study 22516856 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (normal foot alignment)
Number of subjects: 154
Study 19406402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg/day
Number of subjects: 20
Study 18090158 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding with fiber
Number of subjects: 148
Study 18090158 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral feeding with fiber
Number of subjects: 148
Study 18090158 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral feeding without fiber
Number of subjects: 148
Study 18090158 — intervention group
Group type: COMPARATOR
Intervention: Continuous enteral feeding without fiber
Number of subjects: 148
Study 15573736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride at 1-2 mg/kg
Number of subjects: 100
Study 15573736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11489008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian Cancer Trials Intergroup Network
Number of subjects: 0
Study 11489008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologic Cancer Intergroup (GCIG)
Number of subjects: 0
Study 9849445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (200 U/kg body weight daily)
Number of subjects: 54
Study 9849445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7723344 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 26
Study 7723344 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 26
Study 2048592 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol and 1.0 mg norethindrone
Number of subjects: 192
Study 2048592 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 1.0 mg norethindrone
Number of subjects: 192
Study 2048592 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 0.5 mg norethindrone
Number of subjects: 192
Study 2048592 — intervention group
Group type: EXPERIMENTAL
Intervention: Type O women using the highest estrogen dose preparation (50 micrograms)
Number of subjects: 192
Study 2048592 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-type O women using the lowest progestin dose preparation (0.5 mg)
Number of subjects: 192
Study 7031981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO)
Number of subjects: 10
Study 7031981 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 10
Study 31300325 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) robotic simulation
Number of subjects: 58
Study 31300325 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic dry-laboratory simulation training
Number of subjects: 58
Study 31300325 — intervention group
Group type: COMPARATOR
Intervention: Robotic suturing quality
Number of subjects: 58
Study 31144265 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (exercise arm)
Number of subjects: 0
Study 31144265 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 31144265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise arm
Number of subjects: 0
Study 31144265 — intervention group
Group type: EXPERIMENTAL
Intervention: Women farther out from surgery
Number of subjects: 0
Study 31144265 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 28120446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 204
Study 28120446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 204
Study 25212456 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for iron overload
Number of subjects: 0
Study 23689577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus combined with corticosteroids
Number of subjects: 100
Study 23689577 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with corticosteroids
Number of subjects: 100
Study 22164271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ng/kg LPS
Number of subjects: 34
Study 22164271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ng/kg LPS
Number of subjects: 34
Study 22164271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18853166 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antioxidants (glutathione and catalase)
Number of subjects: 37
Study 18853166 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum nitric oxide (NO)
Number of subjects: 37
Study 18853166 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 37
Study 17244850 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program
Number of subjects: 194
Study 17244850 — intervention group
Group type: COMPARATOR
Intervention: Reference group (age- and sex-matched healthy individuals)
Number of subjects: 194
Study 15531491 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 53
Study 15531491 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up (Control)
Number of subjects: 53
Study 12092634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E)
Number of subjects: 144
Study 12092634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9632125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine for 3 months followed by clinic visits
Number of subjects: 132
Study 9632125 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 132
Study 9632125 — intervention group
Group type: COMPARATOR
Intervention: Clinic visits
Number of subjects: 132
Study 9632125 — intervention group
Group type: COMPARATOR
Intervention: Behavioural group therapy
Number of subjects: 132
Study 8291731 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg intravenous (2 ml) ketorolac, followed by 30 mg intravenously (in saline 20 ml) over 30 min every 6 h
Number of subjects: 198
Study 8291731 — intervention group
Group type: COMPARATOR
Intervention: 2 ml intravenous saline, followed by saline 20 ml intravenously over 30 min every 6 h
Number of subjects: 198
Study 3354541 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 379
Study 31409509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER) - 48 hours of 600 kcal/day followed by 5 days of healthy eating advice
Number of subjects: 43
Study 31409509 — intervention group
Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER) - 500 kcal/day healthy eating advice
Number of subjects: 43
Study 31430267 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-crossover analysis
Number of subjects: 0
Study 31430267 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled case series
Number of subjects: 0
Study 31430267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both designs
Number of subjects: 0
Study 28471931 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 87
Study 28471931 — intervention group
Group type: COMPARATOR
Intervention: Non-Team-Based Learning (non-TBL)
Number of subjects: 87
Study 26902043 — intervention group
Group type: COMPARATOR
Intervention: Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study 26902043 — intervention group
Group type: COMPARATOR
Intervention: Acute Normovolemic Hemodilution (ANH) + Controlled Low Central Venous Pressure (LCVP)
Number of subjects: 60
Study 23744953 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block (group TAP) with 20 mL of 0.375% ropivacaine
Number of subjects: 90
Study 23744953 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (group EA) with 8 mL of 0.25% ropivacaine before induction and maintained with 5 mL/h of 0.25% ropivacaine
Number of subjects: 90
Study 23744953 — intervention group
Group type: COMPARATOR
Intervention: IV opioid analgesia (group GA)
Number of subjects: 90
Study 20927038 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 20927038 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 20927038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 19133220 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study 19133220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16675759 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care for major depression
Number of subjects: 926
Study 16675759 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care for bipolar disorder
Number of subjects: 926
Study 16675759 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care for schizophrenia
Number of subjects: 926
Study 16675759 — intervention group
Group type: COMPARATOR
Intervention: Usual care for major depression
Number of subjects: 926
Study 16675759 — intervention group
Group type: COMPARATOR
Intervention: Usual care for bipolar disorder
Number of subjects: 926
Study 16675759 — intervention group
Group type: COMPARATOR
Intervention: Usual care for schizophrenia
Number of subjects: 926
Study 14559046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing training (ST group)
Number of subjects: 47
Study 14559046 — intervention group
Group type: COMPARATOR
Intervention: Manual treatment (MT group)
Number of subjects: 47
Study 10762020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 10762020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Number of subjects: 0
Study 10762020 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Fenretinide (4-HPR)
Number of subjects: 0
Study 8955967 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.025 mg.kg‐1
Number of subjects: 18
Study 8955967 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.050 mg.kg‐1
Number of subjects: 18
Study 8955967 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.050-0.150 mg.kg‐1
Number of subjects: 18
Study 1316584 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 10
Study 1316584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2990890 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 45
Study 2990890 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 45
Study 2990890 — intervention group
Group type: COMPARATOR
Intervention: No contact (Control)
Number of subjects: 45
Study 31433542 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro (FLP) continuous glucose monitor
Number of subjects: 33
Study 29474479 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding promotion by peer counsellors
Number of subjects: 1000
Study 29474479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exclusive breastfeeding promotion)
Number of subjects: 1000
Study 27823869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant 25 mg
Number of subjects: 36
Study 27823869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant 50 mg
Number of subjects: 36
Study 27823869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27823869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (oral)
Number of subjects: 36
Study 24666438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group: standardized training for PHCT professionals, 1 individualized counselling session, 1 family session, and 4 educational group sessions, along with usual home health care visits, periodic telephone follow-up, and unlimited telephone support.
Number of subjects: 282
Study 24666438 — intervention group
Group type: COMPARATOR
Intervention: Control group: usual home health care consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request.
Number of subjects: 282
Study 22963754 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine gel
Number of subjects: 10
Study 22963754 — intervention group
Group type: COMPARATOR
Intervention: 1% tetracaine gel
Number of subjects: 10
Study 22963754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracaine solution
Number of subjects: 10
Study 21064010 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine infusion (1% solution, 8 ml/h, 1.92 g/24 h)
Number of subjects: 42
Study 21064010 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (0.9% saline solution)
Number of subjects: 42
Study 18380127 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 26
Study 18380127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14745070 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (1,500 mg daily)
Number of subjects: 31
Study 14745070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 14745070 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 31
Study 12193977 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg warfarin daily
Number of subjects: 0
Study 12193977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg warfarin daily
Number of subjects: 0
Study 12193977 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg warfarin daily
Number of subjects: 0
Study 12193977 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg phenprocoumon daily
Number of subjects: 0
Study 12193977 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg phenprocoumon daily
Number of subjects: 0